Can Almirall turn dermatology momentum into a stronger long-term innovation engine?
Almirall’s dermatology engine is growing faster than group sales. The next test is whether biologics and pipeline bets can sustain momentum.
Pharma & Biotech
Pharma & Biotech
Why Halozyme’s Hypercon deal with Oruka could matter beyond one psoriasis antibody
Psoriasis biologics are getting longer acting. Halozyme and Oruka now face the harder test of making high-dose therapy practical.
Pharma & Biotech
Ustekinumab biosimilar approved in Japan: Can Samsung Bioepis expand its global autoimmune footprint?
Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia's biosimilar adoption. Find out what this means.